Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Yi Hui Pan"'
Autor:
Kang-Bo Huang, Cheng-Peng Gui, Yun-Ze Xu, Xue-Song Li, Hong-Wei Zhao, Jia-Zheng Cao, Yu-Hang Chen, Yi-Hui Pan, Bing Liao, Yun Cao, Xin-Ke Zhang, Hui Han, Fang-Jian Zhou, Ran-Yi Liu, Wen-Fang Chen, Ze-Ying Jiang, Zi-Hao Feng, Fu-Neng Jiang, Yan-Fei Yu, Sheng-Wei Xiong, Guan-Peng Han, Qi Tang, Kui Ouyang, Gui-Mei Qu, Ji-Tao Wu, Ming Cao, Bai-Jun Dong, Yi-Ran Huang, Jin Zhang, Cai-Xia Li, Pei-Xing Li, Wei Chen, Wei-De Zhong, Jian-Ping Guo, Zhi-Ping Liu, Jer-Tsong Hsieh, Dan Xie, Mu-Yan Cai, Wei Xue, Jin-Huan Wei, Jun-Hang Luo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Integrating genomics and histology for cancer prognosis demonstrates promise. Here, we develop a multi-classifier system integrating a lncRNA-based classifier, a deep learning whole-slide-image-based classifier, and a clinicopathological cla
Externí odkaz:
https://doaj.org/article/c0dc0f9c92514591b5800e5499188a06
Autor:
Hong-wei Zhao, Jian Li, Jia-Zheng Cao, Juan Lin, Zhu Wang, Jian-yao Lv, Jin-huan Wei, Zhen-hua Chen, Hao-hua Yao, Yi-hui Pan, Zhen-li Gao, Jun-hang Luo, Wei Chen, Lei Shi, Yong Fang
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background To investigate the value of using contrast-enhanced transrectal ultrasound (CETRUS) to reduce unnecessary collection of biopsies during prostate cancer diagnosis and its utility in predicting biochemical recurrence in patients wit
Externí odkaz:
https://doaj.org/article/563b26e945b54437bc9ed75d5d235cd0
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundOnly a proportion of patients with bladder cancer may benefit from durable response to immune checkpoint inhibitor (ICI) therapy. More precise indicators of response to immunotherapy are warranted. Our study aimed to construct a more precis
Externí odkaz:
https://doaj.org/article/1b559ccb71774e748902c3f8d65e22db
Autor:
Jun Lu, Liang-min Fu, Yun Cao, Yong Fang, Jia-zheng Cao, Yi-hui Pan, Jun-jie Cen, Yan-ping Liang, Zhen-hua Chen, Jin-huan Wei, Yong Huang, Mukhtar Adan Mumin, Quan-hui Xu, Ying-han Wang, Jiang-quan Zhu, Hui Liang, Zhu Wang, Qiong Deng, Wei Chen, Xiao-han Jin, Zhi-ping Liu, Jun-hang Luo
Publikováno v:
Oncogene. 42:1543-1557
LZTFL1 is a tumor suppressor located in chromosomal region 3p21.3 that is deleted frequently and early in various cancer types including the kidney cancer. However, its role in kidney tumorigenesis remains unknown. Here we hypothesized a tumor suppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd89cf38583b112cf74017712eb35a55
https://doi.org/10.1038/s41388-023-02666-x
https://doi.org/10.1038/s41388-023-02666-x
Autor:
Li-Zhen Zhang, Liang-Min Fu, Lei Tan, Yi-Hui Pan, Jinhuan Wei, Pengju Li, Wei Chen, Zhenhua Chen, Hao-Hua Yao, Junhang Luo, Guan-Nan Shu, Mingxiao Zhang, Jiaying Li, Jian-Ping Guo, Yiming Tang, Jun Lu, Zhuangyao Liao, Zihao Feng
Publikováno v:
Oncogene
Long noncoding RNAs (lncRNAs) have been reported to exert important roles in tumors, including clear cell renal cell carcinoma (ccRCC). PVT1 is an important oncogenic lncRNA which has critical effects on onset and development of various cancers, howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd77e9acfb1cbb3e59f28806bff84fa8
https://doi.org/10.1038/s41388-021-01971-7
https://doi.org/10.1038/s41388-021-01971-7
Autor:
Yiming Tang, Yi-Hui Pan, Yunlin Ye, Lei Tan, Yong Huang, Wei Chen, Junhang Luo, Jiazheng Cao, Pengju Li, Yu-Hang Chen, Zhenhua Chen, Jinhuan Wei, Zike Qin, Jun Lu, Hao-Hua Yao, Chengpeng Gui
Publikováno v:
Genomics. 113:740-754
Clear-cell renal cell carcinoma (ccRCC) carries a variable prognosis. Prognostic biomarkers can stratify patients according to risk, and can provide crucial information for clinical decision-making. We screened for an autophagy-related long non-codin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb1414a2e49b02521025a8b796857a7b
https://doi.org/10.1016/j.ygeno.2021.01.016
https://doi.org/10.1016/j.ygeno.2021.01.016
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
BackgroundOnly a proportion of patients with bladder cancer may benefit from durable response to immune checkpoint inhibitor (ICI) therapy. More precise indicators of response to immunotherapy are warranted. Our study aimed to construct a more precis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eefb73d75b5a351d6c99a24049907e40
http://europepmc.org/articles/PMC8371040
http://europepmc.org/articles/PMC8371040
Autor:
Mi Zhou, Jiaxing Zhang, Yi-Hui Pan, Guan-Nan Shu, Wei Chen, Hui Han, Kang-Bo Huang, Zhousan Zheng, Zhenhua Chen, Jinhuan Wei, Zihao Feng, Jun Lu, Junhang Luo, Xi Liu, Hao-Hua Yao
Publikováno v:
Cancer letters. 523
Sunitinib resistance is a major challenge in systemic therapy for renal cell carcinoma (RCC). The role of circular RNAs (circRNAs) in regulating sunitinib resistance of RCC is largely unknown. We established sunitinib-resistant RCC cell lines in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cd0a22a99b9c18c7bc1499e607cdd1c
https://pubmed.ncbi.nlm.nih.gov/34626691
https://pubmed.ncbi.nlm.nih.gov/34626691
Autor:
Yi-Hui Pan, Yuan Bian, Man Wang, Hong-Yu Liang, Cong-Cong Hou, Duan-Yuan Cao, Ding Zhao, Lili Zhao
Publikováno v:
BioMetals. 32:785-794
This study was conducted to investigate the damage caused by vanadium compounds and to explore the protective effects of berberine (BBR) in human umbilical vein endothelial cells (HUVECs). BBR is a biologically active small molecule found in Coptis r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c477572c0fa98c32b35833bcb1f49e92
https://doi.org/10.1007/s10534-019-00211-6
https://doi.org/10.1007/s10534-019-00211-6
Autor:
Fang Jian Zhou, Bo Li, Ji Tao Wu, Shaogang Wang, Jin Huan Wei, Dan Xie, Bing Liao, Jin Zhang, Yi Hui Pan, Yun Cao, Guo-Ping Wang, Zhen Li Gao, Zhi Ling Zhang, Gui Mei Qu, Zhi Ping Liu, Yunze Xu, Wei Chen, Cong Liu, Zhen Hua Chen, Pei Xing Li, Cai Xia Li, Hui Han, Jun Lu, Qiang Liu, Lei Shi, Jun Hang Luo, Hong Wei Zhao, Wei Xue, Wen Fang Chen, Yi Ran Huang, Qing Wang, Hao Hua Yao, Zi Hao Feng
Publikováno v:
The Lancet Oncology. 20:591-600
Summary Background Identification of high-risk localised renal cell carcinoma is key for the selection of patients for adjuvant treatment who are at truly higher risk of reccurrence. We developed a classifier based on single-nucleotide polymorphisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b80697c42185f8f74af333370f860049
https://doi.org/10.1016/s1470-2045(18)30932-x
https://doi.org/10.1016/s1470-2045(18)30932-x